Karyopharm Therapeutics Inc. (KPTI) Forms $18.99 Double Top; Leuthold Group Trimmed Convergys Corp. (CVG) Holding By $309,056

Convergys Corporation (NYSE:CVG) Logo

Leuthold Group Llc decreased Convergys Corp. (CVG) stake by 14.89% reported in 2018Q1 SEC filing. Leuthold Group Llc sold 14,048 shares as Convergys Corp. (CVG)’s stock rose 2.40%. The Leuthold Group Llc holds 80,284 shares with $1.82M value, down from 94,332 last quarter. Convergys Corp. now has $2.27B valuation. The stock increased 0.24% or $0.06 during the last trading session, reaching $24.8. About 70,854 shares traded. Convergys Corporation (NYSE:CVG) has declined 0.75% since June 25, 2017 and is downtrending. It has underperformed by 13.32% the S&P500. Some Historical CVG News: 11/05/2018 – CONVERGYS KICKED OFF SALES PROCESS AFTER ITS CEO DECIDED TO STEP DOWN AND IS DEEP INTO DISCUSSIONS WITH A NUMBER OF PARTIES – WSJ, CITING; 08/05/2018 – Convergys 1Q Adj EPS 41c; 08/05/2018 – Convergys Raises Quarter Dividend to 11c; 08/05/2018 – Convergys 1Q Rev $674.2M; 19/03/2018 Convergys Releases Enterprise Voice of the Customer Software to Help Companies Transform the Way They Use Feedback; 16/04/2018 – Convergys Accelerates Deployment of Robotic Process Automation (RPA) to More Than One-Third of its Workforce to Streamline; 16/05/2018 – Convergys sees limited interest in second round; 08/05/2018 – Convergys 1Q EPS 30c; 25/04/2018 – As Intelligent Customer Care Platforms Experience Rapid Growth, Convergys Introduces Conversational Virtual Assistant Technology to Leading North American Financial Institution; 08/05/2018 – CONVERGYS CORP – CONFIRMING 2018 GUIDANCE

Karyopharm Therapeutics Inc. (KPTI) formed double top with $19.56 target or 3.00% above today’s $18.99 share price. Karyopharm Therapeutics Inc. (KPTI) has $1.14B valuation. The stock increased 1.66% or $0.31 during the last trading session, reaching $18.99. About 100,376 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 94.50% since June 25, 2017 and is uptrending. It has outperformed by 81.93% the S&P500. Some Historical KPTI News: 07/05/2018 – Karyopharm Therapeutics: Gross Proceeds From Offering Expected to Be $155 Million; 07/05/2018 – Karyopharm Therapeutics Announces Closing of Public Offering of Common Stk and Exercise in Full of Underwriters’ Option to Purchase Additional Shrs; 10/04/2018 – KARYOPHARM THERAPEUTICS INC – EXPECTS TO REPORT TOP-LINE DATA FROM STORM STUDY AT END OF APRIL 2018; 15/03/2018 – KARYOPHARM THERAPEUTICS INC – TOP-LINE DATA FROM PHASE 2B STORM STUDY EXPECTED END OF APRIL 2018; 24/05/2018 – KARYOPHARM THERAPEUTICS INC – KARYOPHARM ELIGIBLE TO RECEIVE UP TO $150 MLN (USD) IN FUTURE MILESTONES, PLUS ROYALTIES; 15/03/2018 – KARYOPHARM 4Q LOSS/SHR 80C, EST. LOSS/SHR 60C; 17/05/2018 – Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting; 24/05/2018 – KARYOPHARM THERAPEUTICS INC – TOTAL DEAL VALUED AT UP TO $162 MLN; 30/04/2018 – Karyopharm Therapeutics: Plans to Submit a New Drug Application to the FDA in the 2H of 2018; 15/03/2018 – KARYOPHARM CASH & OTHER $176.4M

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on August, 14. They expect $-0.76 earnings per share, down 18.75% or $0.12 from last year’s $-0.64 per share. After $-0.78 actual earnings per share reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -2.56% EPS growth.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. Karyopharm Therapeutics Inc. had 39 analyst reports since August 11, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of KPTI in report on Tuesday, May 1 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, June 23. The rating was maintained by Jefferies on Friday, March 16 with “Buy”. The firm has “Overweight” rating given on Wednesday, September 2 by JP Morgan. The stock has “Hold” rating by Jefferies on Wednesday, January 6. The rating was maintained by RBC Capital Markets with “Buy” on Monday, October 16. On Tuesday, March 15 the stock rating was downgraded by Bank of America to “Underperform”. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Outperform” rating given on Tuesday, June 28 by Robert W. Baird. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, November 2. Jefferies maintained the stock with “Buy” rating in Thursday, October 12 report.

Investors sentiment decreased to 1.52 in 2018 Q1. Its down 0.04, from 1.56 in 2017Q4. It is negative, as 11 investors sold Karyopharm Therapeutics Inc. shares while 20 reduced holdings. 15 funds opened positions while 32 raised stakes. 30.12 million shares or 0.45% less from 30.26 million shares in 2017Q4 were reported. Manufacturers Life Insur The holds 0% or 25,929 shares in its portfolio. Ghost Tree Ltd holds 0.21% or 76,786 shares. C Ww Grp Inc Holding A S reported 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). 20,300 were reported by Dekabank Deutsche Girozentrale. Bancorporation Of America De owns 44,892 shares. Amer Grp accumulated 22,713 shares. Citadel Advsrs Limited Liability Company reported 93,940 shares or 0% of all its holdings. Iguana Mngmt Llc owns 125,000 shares or 1.1% of their US portfolio. Wells Fargo Mn reported 0% stake. Art Advisors Lc holds 0.01% or 14,816 shares in its portfolio. D E Shaw And holds 175,541 shares or 0% of its portfolio. Moreover, State Of Wisconsin Investment Board has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 26,000 shares. Trexquant Inv L P has 31,017 shares. Legal And General Gp Plc holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 6,413 shares. Vanguard Grp Inc, Pennsylvania-based fund reported 1.94M shares.

Since January 8, 2018, it had 0 insider buys, and 32 selling transactions for $3.84 million activity. $172,991 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were sold by Kauffman Michael. 2,500 shares were sold by Primiano Christopher Brett, worth $40,076. Shacham Sharon had sold 10,000 shares worth $100,769. Shares for $40,000 were sold by Mirza Mansoor Raza.

Analysts await Convergys Corporation (NYSE:CVG) to report earnings on August, 14. They expect $0.36 EPS, down 21.74% or $0.10 from last year’s $0.46 per share. CVG’s profit will be $32.94 million for 17.22 P/E if the $0.36 EPS becomes a reality. After $0.41 actual EPS reported by Convergys Corporation for the previous quarter, Wall Street now forecasts -12.20% negative EPS growth.

Since March 5, 2018, it had 0 insider buys, and 2 insider sales for $777,901 activity. Ayers Andrea J. sold $697,413 worth of Convergys Corporation (NYSE:CVG) on Monday, March 5. Greenwald Taylor C sold $80,488 worth of Convergys Corporation (NYSE:CVG) on Wednesday, March 14.

Among 8 analysts covering Convergys Corp (NYSE:CVG), 0 have Buy rating, 0 Sell and 8 Hold. Therefore 0 are positive. Convergys Corp had 17 analyst reports since August 14, 2015 according to SRatingsIntel. The rating was upgraded by Zacks to “Sell” on Wednesday, August 26. Wells Fargo downgraded the shares of CVG in report on Thursday, February 25 to “Market Perform” rating. Zacks upgraded Convergys Corporation (NYSE:CVG) on Friday, August 14 to “Sell” rating. The stock of Convergys Corporation (NYSE:CVG) has “Neutral” rating given on Wednesday, October 21 by Sidoti. The rating was upgraded by Sidoti to “Buy” on Wednesday, January 6. On Wednesday, August 10 the stock rating was maintained by Citigroup with “Neutral”. As per Monday, October 9, the company rating was maintained by SunTrust. The stock of Convergys Corporation (NYSE:CVG) earned “Hold” rating by Zacks on Friday, September 4. As per Monday, April 4, the company rating was downgraded by Sidoti. The company was maintained on Friday, September 15 by Robert W. Baird.

Convergys Corporation (NYSE:CVG) Institutional Positions Chart